BellBrook Labs
BellBrook has been developing enabling HTS assays to accelerate enzyme-targeted drug discovery since 2006. Our Transcreener® and AptaFluor® HTS enzyme assays, the only HTS platforms for direct detection of nucleotides, enable simple, reliable inhibitor screening and profiling for thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, cGAS, helicases, and glycosyltransferases. To keep pace with the increasing diversity of enzymes being targeted due to advances in genetic and computational methods, we recently introduced Enzolution™ HTS Enzyme Assays, complete solutions including validated recombinant enzymes, substrates, and optimized protocols, and powered by our reliable Transcreener detection reagents. In the past two years, we have built out a portfolio of Enzolution assays for enzymes involved in DNA damage repair and innate immune responses, including DNA and RNA helicases, oligoadenylate synthetases (e.g., cGAS), exonucleases, ectonucleotidases, and poly-ADP-ribosylation enzymes.We have been providing products and services to the drug discovery community for over 20 years because we are passionate about the potential for modulating enzyme function to alleviate disease, and we welcome the technical challenges of developing robust HTS-compatible assays (in this regard, we may even be a bit nerdy). We know that having a convenient, robust and reliable biochemical assay can be the difference between winning or losing the race to a first-in-class drug molecule. And we are proud that our products and services have been used by hundreds of pharmaceutical, biotech and academic customers around the world to develop more effective drugs for treating cancer, metabolic and cardiovascular conditions, autoimmune and inflammatory disorders, and other debilitating diseases.Content by BellBrook Labs
BellBrook Labs has not yet contributed any content.
